Occlugel SAS Secures $100

Occlugel SAS, a company specializing in innovative degradable drug delivery systems, has secured $100,000 in investment capital from investors.

This funding round marks a significant step for the company as it continues to advance its proprietary technologies in the medical field.

Occlugel is known for developing new degradable drug delivery systems (DDDS) designed for loco-regional treatments, offering tunable local delivery of substances like antibiotics, glaucoma treatments, or pain killers over periods ranging from a few days to several weeks.

The company's DDDS are engineered for ease of injection, both per- and post-operatively, aiming to enhance safety for physicians and provide benefits for patients while aligning with health insurance requirements.

Occlugel possesses a strong track record, having previously created and developed the world's first degradable microspheres for embolization and chemoembolization, which were successfully transferred to a US industrial partner.

More recently, an original technology for microspheres with X-ray and MRI visibility was transferred to a European pharmaceutical group.

This new capital infusion will enable Occlugel SAS to further develop its innovative and disruptive DDDS, facilitating a swift market access strategy with high potential for differentiation.

The company plans to utilize the funds to accelerate research and development efforts, expand its operational capabilities, and strengthen its expertise in process transferring of technologies towards industry partners.

Occlugel is actively seeking to establish long-standing relationships to further develop and commercialize its new DDDS, underscoring its commitment to bringing advanced medical solutions to market.